TABLE 2 .
Number of DEGs with a change of greater than ±1.5-fold, a P value of < 0.05, and an FDR of <0.1%
| Condition 1 (no. of subjects) | Condition 2 (no. of subjects) | No. of DEGs at: |
|||
|---|---|---|---|---|---|
| V1k | V2l | V5m | All time points | ||
| All Lyme disease (29) | Control (13) | 1,235 | 1,060 | 686 | 644 |
| Resolved Lyme disease (15) | Control (13) | 1,021 | 1,090 | 238 | 524 |
| Persistent symptomsa (13) | Control (13) | 1,358 | 576 | 181 | 641 |
| Persistent symptomsa (13) | Resolved Lyme disease (15) | 0 | 0 | 0 | 1d |
| Non-PTLDSb (9) | Resolved Lyme disease (15) | 0 | 0 | 0 | 1e |
| PTLDSc (4) | Resolved Lyme disease (15) | 1f | 0 | 0 | 3g |
| PTLDSc (4) | Resolved Lyme disease + non-PTLDSb (24) | 0 | 0 | 0 | 2h |
| Disseminated EM (12) | Single EM (17) | 0 | 0 | 0 | 0 |
| Seronegative (8) | Seropositive (20) | 1i | 0 | 0 | 4j |
| Control (8) | Control (5) | NAn | NA | NA | 0 |
a
All patients with persistent symptoms following treatment completion.
b
Non-PTLDS (persistent symptoms with no functional decline).
c
PTLDS (persistent symptoms with functional decline).
d
GPR15.
e
MIAT.
f
GPR15.
g
CCDC163P, GRP15, ZNF266.
h
GPR15, ZNF266.
i
HLA-DQB1.
j
HLA-DQA1, HLA-DQB1, HLA-DRB5, NSA2.
k
Acute Lyme disease diagnosis, pretreatment.
l
After 3-week antibiotic treatment.
m
At 6 months post-treatment.
n
NA, not applicable.